Evidence map›Paper›PMID 37462441›Full record

ArticleJournal of the Chinese Medical Association : JCMA2023

Dual angiotensin receptor and neprilysin inhibitor reduced portal pressure through peripheral vasodilatation and decreasing systemic arterial pressure in cirrhotic rats.

Chon Kit Pun, Ching-Chih Chang, Chiao-Lin Chuang, Hui-Chun Huang, Shao-Jung Hsu, Yi-Hsiang Huang, Ming-Chih Hou, Fa-Yauh Lee

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the Chinese Medical Association : JCMA, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. The Renin-Angiotensin System in Liver Disease.International journal of molecular sciences · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Chon Kit PunFaculty of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC.
Ching-Chih ChangFaculty of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC.
Chiao-Lin ChuangFaculty of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC.
Hui-Chun HuangFaculty of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC.
Shao-Jung HsuFaculty of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC.
Yi-Hsiang HuangFaculty of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC.
Ming-Chih HouFaculty of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC.
Fa-Yauh LeeFaculty of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC.
National Yang Ming Chiao Tung University · TWTaipei Veterans General Hospital · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPortal hypertension develops along with the progression of liver cirrhosis. Natriuretic peptides have been shown to reduce portal pressure but concomitantly activate the renin-angiotensin-aldosterone system (RAAS). Angiotensin receptor-neprilysin inhibitors (ARNIs) upregulate natriuretic peptides and avoid the adverse effects of RAAS activation. ARNIs have been shown to reduce portal pressure in rats with pre-hepatic portal hypertension, which involves relatively little liver injury. This study aimed to evaluate the relevant effects of an ARNI in rats with both liver cirrhosis and portal hypertension.

methodsMale Sprague-Dawley rats received common bile duct ligation to induce liver cirrhosis and portal hypertension. Sham-operated rats served as surgical controls. All rats were randomly allocated into three groups to receive distilled water (vehicle), LCZ696 (an ARNI), or valsartan for 4 weeks. Portal hypertension and relevant derangements were assessed after treatment.

resultsPortal hypertension and hyperdynamic circulation developed in the cirrhotic rats. In the rats with cirrhosis and portal hypertension, both LCZ696 and valsartan reduced portal hypertension, mean arterial pressure, and systemic vascular resistance. The decrease in portal pressure was highly associated with the reduction in arterial pressure and systemic vascular resistance. Blood flow in hepatic, splanchnic, and portosystemic collateral systems was not altered. LCZ696 did not significantly influence liver injury or plasma cytokine levels. Liver fibrosis and splanchnic angiogenesis were not affected.

conclusionARNI treatment exerted portal pressure lowering effects via peripheral vasodilatation and decreasing systemic arterial pressure in the rats with liver cirrhosis and portal hypertension. Caution should be taken when using ARNIs in liver cirrhosis.

Indexed as

Arterial PressureHypertension, PortalAnimalsAntihypertensive AgentsAntiviral AgentsLiver CirrhosisMaleNeprilysinPortal PressureRatsRats, Sprague-DawleyReceptors, AngiotensinValsartanVasodilationAntihypertensive AgentsAntiviral AgentsNeprilysinReceptors, AngiotensinValsartan

Identifiers

PMID37462441
PMCPMC12755708
OpenAlexW4384627164

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.